Biomédecine translationnelle

  • ISSN: 2172-0479
  • Indice h du journal: 16
  • Note de citation du journal: 5.91
  • Facteur d’impact du journal: 3.66
Indexé dans
  • Ouvrir la porte J
  • Genamics JournalSeek
  • JournalTOCs
  • RechercheBible
  • Le facteur d'impact global (GIF)
  • Infrastructure nationale des connaissances en Chine (CNKI)
  • CiteFactor
  • Scimago
  • Bibliothèque des revues électroniques
  • Répertoire d'indexation des revues de recherche (DRJI)
  • OCLC - WorldCat
  • Invocation de Proquête
  • Publions
  • MIAR
  • Commission des bourses universitaires
  • Fondation genevoise pour la formation et la recherche médicales
  • Google Scholar
  • SHERPA ROMÉO
  • Laboratoires secrets des moteurs de recherche
  • ResearchGate
Partager cette page

Abstrait

Synthetic Biology in Drug Discovery as a Source of Discovery in Translation Biomedicine

Kevin Buja

The declining cost of DNA synthesis, improvements in genetic engineering, expanding knowledge of genome organisation, and boom in data science, the influence of synthetic biology on the world has been escalating [1]. But a lot of the discipline's use in the pharmaceutical sector is still unclear. The influence of synthetic biology on target validation, assay development, hit discovery, lead optimization, chemical synthesis, and the creation of cellular therapies is highlighted in this review's current examples. We also emphasise the accessibility of the technology and resources powering the field [2]. All phases of drug discovery and development are undoubtedly impacted by synthetic biology, and the prospects for the drug discovery and development value chain may grow as a result of the discipline's contribution being acknowledged [3].